In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally ailment progression or maybe the members are not able to tolerate the study drugs. For all movement cytometry experiments, 10,000 cells per replicate have been https://lloydc322nzj5.wikijm.com/user